Apyx Medical (APYX) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	0-12183
Entity Registrant Name	APYX MEDICAL CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2644611
Entity Address, Address Line One	5115 Ulmerton Road,
Entity Address, City or Town	Clearwater
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33760
City Area Code	727
Local Phone Number	384-2323
Title of 12(b) Security	Common Stock
Trading Symbol	APYX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,597,822
Entity Central Index Key	0000719135
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 14,833	$ 30,870
Trade accounts receivable, net of allowance of $634 and $430	9,094	13,038
Income tax receivables	7,545	7,642
Other receivables	19	483
Inventories, net of provision for obsolescence of $379 and $263	12,042	6,778
Prepaid expenses and other current assets	2,774	1,926
Total current assets	46,307	60,737
Property and equipment, net of accumulated depreciation and amortization of $5,335 and $5,316	6,810	6,575
Operating lease right-of-use assets	774	121
Finance lease right-of-use assets	124	178
Other assets	1,253	1,110
Total assets	55,268	68,721
Current liabilities:
Accounts payable	2,070	2,631
Accrued expenses and other current liabilities	8,842	10,287
Current portion of operating lease liabilities	240	122
Current portion of finance lease liabilities	42	165
Total current liabilities	11,194	13,205
Long-term operating lease liabilities	454	0
Long-term finance lease liabilities	78	18
Long-term contract liabilities	1,192	1,323
Other liabilities	133	166
Total liabilities	13,051	14,712
EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,588,398 issued and outstanding as of September 30, 2022, and 34,409,912 issued and outstanding as of December 31, 2021	35	34
Additional paid-in capital	71,641	66,221
Accumulated deficit	(29,686)	(12,551)
Total stockholders’ equity	41,990	53,704
Non-controlling interest	227	305
Total equity	42,217	54,009
Total liabilities and equity	$ 55,268	$ 68,721

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 634	$ 430
Inventories, provision for obsolescence	379	263
Accumulated depreciation and amortization	$ 5,335	$ 5,316
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	34,588,398	34,409,912
Common stock, shares outstanding (in shares)	34,588,398	34,409,912

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Sales	$ 9,114	$ 11,831	$ 31,899	$ 31,693
Cost of sales	3,357	3,775	11,009	10,243
Gross profit	5,757	8,056	20,890	21,450
Other costs and expenses:
Research and development	1,061	1,175	3,289	3,374
Professional services	1,936	2,032	6,611	5,442
Salaries and related costs	3,871	4,206	13,944	12,794
Selling, general and administrative	4,671	4,611	14,675	12,596
Total other costs and expenses	11,539	12,024	38,519	34,206
Loss from operations	(5,782)	(3,968)	(17,629)	(12,756)
Interest income	73	2	93	9
Interest expense	(1)	(3)	(12)	(9)
Other (loss) income, net	(35)	(192)	551	(188)
Total other income (loss), net	37	(193)	632	(188)
Loss before income taxes	(5,745)	(4,161)	(16,997)	(12,944)
Income tax expense	50	73	216	246
Net loss	(5,795)	(4,234)	(17,213)	(13,190)
Net loss attributable to non-controlling interest	(31)	(12)	(78)	(21)
Net loss attributable to stockholders	$ (5,764)	$ (4,222)	$ (17,135)	$ (13,169)
Loss per share:
Basic (in dollars per share)	$ (0.17)	$ (0.12)	$ (0.50)	$ (0.38)
Diluted (in dollars per share)	$ (0.17)	$ (0.12)	$ (0.50)	$ (0.38)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2020		34,289
Beginning balance at Dec. 31, 2020	$ 63,859	$ 34	$ 61,066	$ 2,621	$ 138
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	195				195
Shares issued on stock options exercises for cash (in shares)		11
Shares issued on stock options exercises for cash	49		49
Stock based compensation	3,747		3,747
Shares issued on net settlement of stock options (in shares)		40
Net loss	(13,190)			(13,169)	(21)
Ending balance (in shares) at Sep. 30, 2021		34,340
Ending balance at Sep. 30, 2021	54,660	$ 34	64,862	(10,548)	312
Beginning balance (in shares) at Jun. 30, 2021		34,323
Beginning balance at Jun. 30, 2021	57,682	$ 34	63,650	(6,326)	324
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		3
Shares issued on stock options exercises for cash	28		28
Stock based compensation	1,184		1,184
Shares issued on net settlement of stock options (in shares)		14
Net loss	(4,234)			(4,222)	(12)
Ending balance (in shares) at Sep. 30, 2021		34,340
Ending balance at Sep. 30, 2021	54,660	$ 34	64,862	(10,548)	312
Beginning balance (in shares) at Dec. 31, 2021		34,410
Beginning balance at Dec. 31, 2021	54,009	$ 34	66,221	(12,551)	305
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		106
Shares issued on stock options exercises for cash	365	$ 1	364
Stock based compensation	5,056		5,056
Shares issued on net settlement of stock options (in shares)		72
Net loss	(17,213)			(17,135)	(78)
Ending balance (in shares) at Sep. 30, 2022		34,588
Ending balance at Sep. 30, 2022	42,217	$ 35	71,641	(29,686)	227
Beginning balance (in shares) at Jun. 30, 2022		34,493
Beginning balance at Jun. 30, 2022	46,163	$ 34	69,793	(23,922)	258
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		62
Shares issued on stock options exercises for cash	157	$ 1	156
Stock based compensation	1,692		1,692
Shares issued on net settlement of stock options (in shares)		33
Net loss	(5,795)			(5,764)	(31)
Ending balance (in shares) at Sep. 30, 2022		34,588
Ending balance at Sep. 30, 2022	$ 42,217	$ 35	$ 71,641	$ (29,686)	$ 227

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (17,213)	$ (13,190)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	688	674
Provision for inventory obsolescence	158	15
Loss on disposal of property and equipment	76	47
Stock based compensation	5,056	3,747
Provision for allowance for doubtful accounts	283	57
Changes in operating assets and liabilities:
Trade receivables	3,273	(3,168)
Prepaid expenses and other assets	(521)	(23)
Income tax receivables	97	0
Inventories	(5,672)	(1,982)
Accounts payable	(439)	1,555
Accrued and other liabilities	(1,536)	1,605
Net cash used in operating activities	(15,750)	(10,663)
Cash flows from investing activities
Purchases of property and equipment	(868)	(391)
Net cash used in investing activities	(868)	(391)
Cash flows from financing activities
Proceeds from stock option exercises	365	49
Repayment of finance lease liabilities	(138)	(181)
Contributions from non-controlling interests	0	195
Net cash provided by financing activities	227	63
Effect of exchange rates on cash	354	(26)
Net change in cash and cash equivalents	(16,037)	(11,017)
Cash and cash equivalents, beginning of period	30,870	41,915
Cash and cash equivalents, end of period	14,833	30,898
Cash paid for:
Interest	12	8
Income taxes	128	13
Non cash activities:
Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification	769	0
Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease	103	0
Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification	$ 28	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Safety Communication that warns consumers and health care providers against the use of the Company’s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology. On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for certain skin contraction procedures. On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion® Dermal handpiece, and the expanded indications for the Renuvion® APR handpieces. The 510(k) clearance for the Renuvion® Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion® APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the nine months ended September 30, 2022, the Company incurred an operating loss of $17.6 million and used $15.8 million of cash in operations. As of September 30, 2022, the Company had cash and cash equivalents of $14.8 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. In an effort to alleviate these conditions, management is currently evaluating various funding alternatives to improve liquidity and may seek to raise additional capital through debt financing, the sale of equity securities, leveraging its unencumbered real estate, or any combination thereof. In addition, management is actively pursuing collection of the Company’s income tax receivable. Management also continues to re-assess its operating expenditures and cost structure to be commensurate with its expected levels of revenue and has the ability to reduce or delay expenditures to enhance and preserve liquidity. As the Company seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company’s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, the Company’s performance and investor sentiment with respect to the Company and its industry. Management believes that the actions and efforts it can and will take to manage operating expenditures and, while not assured, arrange alternative financing sources as described above will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about its ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year. Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.

DISPOSAL OF BUSINESS

DISPOSAL OF BUSINESS	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISPOSAL OF BUSINESS	DISPOSAL OF BUSINESS On August 30, 2018, the Company closed on a definitive asset purchase agreement (the “Asset Purchase Agreement”) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company divested and sold the Company ’ s electrosurgical “Core” business segment and related intellectual property, including the Bovie® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, which expired August 30, 2022, whereby it manufactured certain Core pro ducts and sold them to Symmetry at agreed upon prices. Any activity resulting from this agreement was netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). There was no significant Core activity for the three months ended September 30, 2022. Core activity for the three months ended September 30, 2021, amounted to $1.6 million with cost of sales equivalents of $1.3 million and related other expenses of $0.5 million for net other loss of $0.3 million. Core activity for the nine months ended September 30, 2022 , amounted to $0.6 million with cost of sales equivalents of $0.5 million and other related expenses of $0.1 million for net other loss of $0.1 million. Core activity for the nine months ended September 30, 2021 , amounted to $5.2 million with cost of sales equivalents of $4.4 million and net other related operating expenses of $1.1 million for net other loss of $0.3 million.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 5,078 $ 3,603 Work in process 2,414 1,441 Finished goods 4,929 1,997 Gross inventories 12,421 7,041 Less: provision for obsolescence (379) (263) Inventories, net $ 12,042 $ 6,778

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
LEASES	LEASES Operating Leases The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company’s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. Finance Leases The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: September 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 4.4 4.1 1.0 0.8 Weighted average discount rate 2.75% 2.64% 3.98% 4.00% Maturities of lease liabilities as of September 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 75 $ 10 2023 218 40 2024 111 21 2025 111 21 2026 111 21 Thereafter 111 12 Total lease payments 737 125 Less imputed interest (43) (5) Present value of lease liabilities 694 120 Less current portion of lease liabilities (240) (42) Long-term portion of lease liabilities $ 454 $ 78
LEASES	LEASES Operating Leases The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company’s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. Finance Leases The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: September 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 4.4 4.1 1.0 0.8 Weighted average discount rate 2.75% 2.64% 3.98% 4.00% Maturities of lease liabilities as of September 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 75 $ 10 2023 218 40 2024 111 21 2025 111 21 2026 111 21 Thereafter 111 12 Total lease payments 737 125 Less imputed interest (43) (5) Present value of lease liabilities 694 120 Less current portion of lease liabilities (240) (42) Long-term portion of lease liabilities $ 454 $ 78

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 879 $ 546 Accrued bonuses — 2,117 Accrued commissions 877 1,656 Accrued product warranties 616 593 Accrued product liability claim insurance deductibles 1,016 610 Accrued professional fees and legal related contingent liabilities 1,134 421 Joint and several payroll liability 399 1,027 Short-term contract liabilities 1,145 533 Uncertain tax positions 2,024 1,863 Sales tax payable 135 428 Other accrued expenses and current liabilities 617 493 Total accrued expenses and other current liabilities $ 8,842 $ 10,287 During April 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income, net for the nine months ended September 30, 2022.

CHINA JOINT VENTURE

CHINA JOINT VENTURE	9 Months Ended
	Sep. 30, 2022
Noncontrolling Interest [Abstract]
CHINA JOINT VENTURE	CHINA JOINT VENTURE In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, which had been fully funded as of December 31, 2021. As of the date of these condensed consolidated financial statements, the China JV has not commenced principal operations. Changes in the Company ’ s investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2022 2021 2022 2021 Beginning interest in China JV $ 269 $ 338 $ 317 $ 144 Contributions $ — $ — $ — $ 203 Net loss attributable to Apyx $ (33) $ (13) $ (81) $ (22) Ending interest in China JV $ 236 $ 325 $ 236 $ 325

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to stockholders $ (5,764) $ (4,222) $ (17,135) $ (13,169) Denominator: Weighted average shares outstanding - basic and diluted 34,569 34,330 34,488 34,318 Loss per share: Basic and diluted $ (0.17) $ (0.12) $ (0.50) $ (0.38) Anti-dilutive instruments excluded from diluted loss per common share: Options 6,635 5,534 6,635 5,534

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize. The Company recognized approximately $1,692,000 and $5,056,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2022, as compared with $1,184,000 and $3,747,000, respectively, for the three and nine months ended September 30, 2021. Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2021 5,397,691 $ 5.95 Granted 1,692,419 10.64 Exercised (299,006) 4.57 Canceled and forfeited (155,697) 9.20 Outstanding at September 30, 2022 6,635,409 $ 7.13 The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2022 and 2021, respectively, we received 55,853 and 37,049 options as payment in the exercise of 33,313 and 13,285 options. For the nine months ended September 30, 2022 and 2021, respectively, we received 92,520 and 59,104 options as payment in the exercise of 72,313 and 39,312 options. Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2022 (“2022 Grants”) utilizing a Black-Scholes model. 2022 Grants Strike price $5.10 - $10.56 Risk-free rate 1.6% - 3.9% Expected dividend yield — Expected volatility 69.6% - 78.5% Expected term (in years) 5 - 6

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax expense was approximately $50,000 and $73,000 with effective tax rates of (0.9)% and (1.8)% for the three months ended September 30, 2022 and 2021, respectively. Income tax expense was approximately $216,000 and $246,000 with effective tax rates of (1.3)% and (1.9)% for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September 30, 2022 and 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period, combined with interest and penalties on uncertain tax positions. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September 30, 2022. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September 30, 2022, the Company had approximately $711,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three months ended September 30, 2022 and 2021, respectively, are approximately $54,000 and $52,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense for the nine months ended September 30, 2022 and 2021, respectively, are approximately $160,000 and $152,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $2,024,000 of income tax benefits in the consolidated statement of operations. During June 2022, the Company was notified by the Internal Revenue Service (“IRS”) that it is examining the Company’s 2018, 2019 and 2020 federal income tax returns. The examination is expected to be completed no later than May 2023. It is expected that all of the uncertain tax positions should be resolved with the completion of the IRS examination.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims. The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows. During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses. In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Complaint seeks an unspecified amount of damages. Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses. The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates. Purchase Commitments At September 30, 2022, the Company had purchase commitments totaling approximately $3.1 million, substantially all of which is expected to be purchased within the next fifteen months.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev’s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department. The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2022 and 2021, the Company made purchases from this supplier of approximately $85,000 and $456,000, respectively. For the nine months ended September 30, 2022 and 2021, the Company made purchases from this supplier of approximately $455,000 and $1,102,000, respectively. At September 30, 2022 and December 31, 2021, respectively, the Company owed this supplier approximately $41,000 and $1,000.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment. The Company ’ s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. “ Corporate & Other ” includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 7,080 $ 2,034 $ — $ 9,114 Income (loss) from operations (1,174) 356 (4,964) (5,782) Interest income — — 73 73 Interest expense — — (1) (1) Other loss, net — — (35) (35) Income tax expense — — 50 50 Three Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 10,313 $ 1,518 $ — $ 11,831 Income (loss) from operations 52 328 (4,348) (3,968) Interest income — — 2 2 Interest expense — — (3) (3) Other loss, net — — (192) (192) Income tax expense — — 73 73 Nine Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 26,258 $ 5,641 $ — $ 31,899 Income (loss) from operations (3,765) 1,142 (15,006) (17,629) Interest income — — 93 93 Interest expense — — (12) (12) Other income, net — — 551 551 Income tax expense — — 216 216 Nine Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 27,951 $ 3,742 $ — $ 31,693 Income (loss) from operations (224) 588 (13,120) (12,756) Interest income — — 9 9 Interest expense — — (9) (9) Other loss, net — — (188) (188) Income tax expense — — 246 246 International sales represented approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively, as compared with approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively. Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2022 2021 2022 2021 Sales by Domestic and International Domestic $ 6,997 $ 7,911 $ 22,492 $ 20,860 International 2,117 3,920 9,407 10,833 Total $ 9,114 $ 11,831 $ 31,899 $ 31,693

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.
Recent Accounting Pronouncements	In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.
Inventories	Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation	Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 5,078 $ 3,603 Work in process 2,414 1,441 Finished goods 4,929 1,997 Gross inventories 12,421 7,041 Less: provision for obsolescence (379) (263) Inventories, net $ 12,042 $ 6,778

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lease Costs	Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: September 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 4.4 4.1 1.0 0.8 Weighted average discount rate 2.75% 2.64% 3.98% 4.00%
Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of September 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 75 $ 10 2023 218 40 2024 111 21 2025 111 21 2026 111 21 Thereafter 111 12 Total lease payments 737 125 Less imputed interest (43) (5) Present value of lease liabilities 694 120 Less current portion of lease liabilities (240) (42) Long-term portion of lease liabilities $ 454 $ 78
Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of September 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 75 $ 10 2023 218 40 2024 111 21 2025 111 21 2026 111 21 Thereafter 111 12 Total lease payments 737 125 Less imputed interest (43) (5) Present value of lease liabilities 694 120 Less current portion of lease liabilities (240) (42) Long-term portion of lease liabilities $ 454 $ 78

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 879 $ 546 Accrued bonuses — 2,117 Accrued commissions 877 1,656 Accrued product warranties 616 593 Accrued product liability claim insurance deductibles 1,016 610 Accrued professional fees and legal related contingent liabilities 1,134 421 Joint and several payroll liability 399 1,027 Short-term contract liabilities 1,145 533 Uncertain tax positions 2,024 1,863 Sales tax payable 135 428 Other accrued expenses and current liabilities 617 493 Total accrued expenses and other current liabilities $ 8,842 $ 10,287

CHINA JOINT VENTURE (Tables)

CHINA JOINT VENTURE (Tables)	9 Months Ended
	Sep. 30, 2022
Noncontrolling Interest [Abstract]
Schedule of China Joint Venture	Changes in the Company ’ s investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2022 2021 2022 2021 Beginning interest in China JV $ 269 $ 338 $ 317 $ 144 Contributions $ — $ — $ — $ 203 Net loss attributable to Apyx $ (33) $ (13) $ (81) $ (22) Ending interest in China JV $ 236 $ 325 $ 236 $ 325

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Basic and diluted earnings (loss) per share	The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to stockholders $ (5,764) $ (4,222) $ (17,135) $ (13,169) Denominator: Weighted average shares outstanding - basic and diluted 34,569 34,330 34,488 34,318 Loss per share: Basic and diluted $ (0.17) $ (0.12) $ (0.50) $ (0.38) Anti-dilutive instruments excluded from diluted loss per common share: Options 6,635 5,534 6,635 5,534

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of stock options and stock awards	Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2021 5,397,691 $ 5.95 Granted 1,692,419 10.64 Exercised (299,006) 4.57 Canceled and forfeited (155,697) 9.20 Outstanding at September 30, 2022 6,635,409 $ 7.13
Schedule of option fair value assumptions	The Company calculated the grant date fair value of options granted in 2022 (“2022 Grants”) utilizing a Black-Scholes model. 2022 Grants Strike price $5.10 - $10.56 Risk-free rate 1.6% - 3.9% Expected dividend yield — Expected volatility 69.6% - 78.5% Expected term (in years) 5 - 6

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 7,080 $ 2,034 $ — $ 9,114 Income (loss) from operations (1,174) 356 (4,964) (5,782) Interest income — — 73 73 Interest expense — — (1) (1) Other loss, net — — (35) (35) Income tax expense — — 50 50 Three Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 10,313 $ 1,518 $ — $ 11,831 Income (loss) from operations 52 328 (4,348) (3,968) Interest income — — 2 2 Interest expense — — (3) (3) Other loss, net — — (192) (192) Income tax expense — — 73 73 Nine Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 26,258 $ 5,641 $ — $ 31,899 Income (loss) from operations (3,765) 1,142 (15,006) (17,629) Interest income — — 93 93 Interest expense — — (12) (12) Other income, net — — 551 551 Income tax expense — — 216 216 Nine Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 27,951 $ 3,742 $ — $ 31,693 Income (loss) from operations (224) 588 (13,120) (12,756) Interest income — — 9 9 Interest expense — — (9) (9) Other loss, net — — (188) (188) Income tax expense — — 246 246
Schedule of revenue by geographic area	Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2022 2021 2022 2021 Sales by Domestic and International Domestic $ 6,997 $ 7,911 $ 22,492 $ 20,860 International 2,117 3,920 9,407 10,833 Total $ 9,114 $ 11,831 $ 31,899 $ 31,693

BASIS OF PRESENTATION - NARRATI

BASIS OF PRESENTATION - NARRATIVE (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 30, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from the disposition of Core business	$ 97,000					$ 97,000
Loss from operations		$ 5,782	$ 3,968	$ 17,629	$ 12,756
Cash and cash equivalents		$ 14,833	$ 30,898	14,833	30,898		$ 30,870	$ 41,915
Cash used in operations				$ 15,750	$ 10,663

DISPOSAL OF BUSINESS (Details)

DISPOSAL OF BUSINESS (Details) - USD ($) $ in Millions		3 Months Ended	9 Months Ended		12 Months Ended
	Aug. 30, 2018	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the disposition of Core business	$ 97				$ 97
Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term	4 years
Sales		$ 1.6	$ 0.6	$ 5.2
Cost of sales		1.3	0.5	4.4
Operating expenses		0.5	0.1	1.1
Net other loss		$ 0.3	$ 0.1	$ 0.3

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 5,078	$ 3,603
Work in process	2,414	1,441
Finished goods	4,929	1,997
Gross inventories	12,421	7,041
Less: provision for obsolescence	(379)	(263)
Inventories, net	$ 12,042	$ 6,778

LEASES - Narrative (Details)

LEASES - Narrative (Details)	Sep. 30, 2022
Leases [Abstract]
Operating lease, extension	5 years
Operating lease extension	1 year
Finance lease, term of contract	63 months

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details)	Sep. 30, 2022	Dec. 31, 2021
Operating
Weighted average remaining lease term	4 years 4 months 24 days	1 year
Weighted average discount rate	2.75%	3.98%
Finance
Weighted average remaining lease term	4 years 1 month 6 days	9 months 18 days
Weighted average discount rate	2.64%	4%

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Operating
2022	$ 75
2023	218
2024	111
2025	111
2026	111
Thereafter	111
Total lease payments	737
Less imputed interest	(43)
Present value of lease liabilities	694
Less current portion of lease liabilities	(240)	$ (122)
Long-term portion of lease liabilities	454	0
Finance Lease, Liability, Payment, Due [Abstract]
2022	10
2023	40
2024	21
2025	21
2026	21
Thereafter	12
Total lease payments	125
Less imputed interest	(5)
Present value of lease liabilities	120
Less current portion of lease liabilities	(42)	(165)
Long-term portion of lease liabilities	$ 78	$ 18

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll	$ 879		$ 546
Accrued bonuses	0		2,117
Accrued commissions	877		1,656
Accrued product warranties	616		593
Accrued product liability claim insurance deductibles	1,016		610
Accrued professional fees and legal related contingent liabilities	1,134		421
Joint and several payroll liability	399	$ (650)	1,027
Short-term contract liabilities	1,145		533
Uncertain tax positions	2,024		1,863
Sales tax payable	135		428
Other accrued expenses and current liabilities	617		493
Total accrued expenses and other current liabilities	$ 8,842		$ 10,287

ACCRUED EXPENSES AND OTHER CU_4

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Joint and several payroll liability	$ (399)	$ 650	$ (1,027)

CHINA JOINT VENTURE - Narrative

CHINA JOINT VENTURE - Narrative (Details) - Corporate Joint Venture - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2019
Noncontrolling Interest [Line Items]
Required capital contribution	$ 357
Chinese Supplier
Noncontrolling Interest [Line Items]
Ownership interest		51%

CHINA JOINT VENTURE - Rollforwa

CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV			$ 305
Contributions				$ 195
Net loss attributable to Apyx	$ (31)	$ (12)	(78)	(21)
Ending interest in China JV	227		227
Corporate Joint Venture
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV	269	338	317	144
Contributions	0	0	0	203
Net loss attributable to Apyx	(33)	(13)	(81)	(22)
Ending interest in China JV	$ 236	$ 325	$ 236	$ 325

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share Reconciliation [Abstract]
Net loss attributable to stockholders, basic	$ (5,764)	$ (4,222)	$ (17,135)	$ (13,169)
Net loss attributable to stockholders, diluted	$ (5,764)	$ (4,222)	$ (17,135)	$ (13,169)
Denominator:
Weighted average shares outstanding - basic (in shares)	34,569	34,330	34,488	34,318
Weighted average shares outstanding - diluted (in shares)	34,569	34,330	34,488	34,318
Loss per share:
Basic (in dollars per share)	$ (0.17)	$ (0.12)	$ (0.50)	$ (0.38)
Diluted (in dollars per share)	$ (0.17)	$ (0.12)	$ (0.50)	$ (0.38)
Options
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	6,635	5,534	6,635	5,534

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Stock based compensation	$ 1,692	$ 1,184	$ 5,056	$ 3,747
Stock swaps equity instruments received (in shares)	55,853	37,049	92,520	59,104
Stock swaps (in shares)	33,313	13,285	72,313	39,312

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Options (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of options
Outstanding, beginning of period (in shares) | shares	5,397,691
Granted (in shares) | shares	1,692,419
Exercised (in shares) | shares	(299,006)
Canceled and forfeited (in shares) | shares	(155,697)
Outstanding, end of period (in shares) | shares	6,635,409
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 5.95
Granted (in dollars per share) | $ / shares	10.64
Exercised (in dollars per share) | $ / shares	4.57
Canceled and forfeited (in dollars per shares) | $ / shares	9.20
Outstanding, end of period (in dollars per share) | $ / shares	$ 7.13

STOCK-BASED COMPENSATION - Fair

STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Strike price (in dollars per share)	$ 10.64
Expected dividend yield	0%
Expected term (in years)	5 years
Minimum
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Strike price (in dollars per share)	$ 5.10
Risk-free rate	1.60%
Expected volatility	69.60%
Maximum
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Strike price (in dollars per share)	$ 10.56
Risk-free rate	3.90%
Expected volatility	78.50%
Expected term (in years)	6 years

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 50	$ 73	$ 216	$ 246
Effective income tax rate	(0.90%)	(1.80%)	(1.30%)	(1.90%)
Unrecognized tax benefits	$ 1,313		$ 1,313
Accrued interest and penalties	711		711
Interest and penalties included in income tax expense	54	$ 52	160	$ 152
Uncertain tax positions that would impact effective tax rate	$ 2,024		$ 2,024

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Purchase obligation	$ 3,100
Contract with International Distributor
Loss Contingencies [Line Items]
Costs accrued	250
Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Costs accrued	475
Minimum | Contract with International Distributor
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	250
Minimum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	475
Maximum | Contract with International Distributor
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	1,000
Maximum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	$ 2,500

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Purchases from related party	$ 85	$ 456	$ 455	$ 1,102
Due to related parties	$ 41		$ 41		$ 1

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting [Abstract]
Number of reportable segments			2
Number of operating segments			2
International sales, percent of total revenue	23.20%	33.10%	29.50%	34.20%

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 9,114	$ 11,831	$ 31,899	$ 31,693
Income (loss) from operations	(5,782)	(3,968)	(17,629)	(12,756)
Interest income	73	2	93	9
Interest expense	(1)	(3)	(12)	(9)
Other income (loss), net	(35)	(192)	551	(188)
Income tax expense	50	73	216	246
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	7,080	10,313	26,258	27,951
Income (loss) from operations	(1,174)	52	(3,765)	(224)
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax expense	0	0	0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	2,034	1,518	5,641	3,742
Income (loss) from operations	356	328	1,142	588
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax expense	0	0	0	0
Corporate & Other
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Income (loss) from operations	(4,964)	(4,348)	(15,006)	(13,120)
Interest income	73	2	93	9
Interest expense	(1)	(3)	(12)	(9)
Other income (loss), net	(35)	(192)	551	(188)
Income tax expense	$ 50	$ 73	$ 216	$ 246

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 9,114	$ 11,831	$ 31,899	$ 31,693
Domestic
Segment Reporting Information [Line Items]
Sales	6,997	7,911	22,492	20,860
International
Segment Reporting Information [Line Items]
Sales	$ 2,117	$ 3,920	$ 9,407	$ 10,833